NRSNW (NeuroSense Therapeutics) OCF Yield %: -27.29 (As of Jun. 25, 2026)


NRSNW NeuroSense Therapeutics Ltd NRSNW
29 GF Score
Price $0.21
! 2 Warning Signs
View Full Analysis

What is NeuroSense Therapeutics OCF Yield %?

NeuroSense Therapeutics NRSNW 29 OCF Yield % is -27.29 as of Jun. 25, 2026. GuruFocus rates NRSNW with a GF Score™ of 29/100. The stock has 2 warning signs investors should review. Among 1,419 Biotechnology companies, NeuroSense Therapeutics ranks worse than 74.42% on this metric.

OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.

As of today, NeuroSense Therapeutics's Trailing 12-Month Cash Flow from Operations is $-7.67 Mil, and Market Cap is $0.00 Mil. Therefore, NeuroSense Therapeutics's OCF Yield % for today is -27.29%.

The historical rank and industry rank for NeuroSense Therapeutics's OCF Yield % or its related term are showing as below:

NRSNW' s OCF Yield % Range Over the Past 10 Years
Min: -27.29   Med: 0   Max: -27.29
Current: -27.29

During the past 7 years, the highest OCF Yield % of NeuroSense Therapeutics was -27.29%. The lowest was -27.29%. And the median was %.

NRSNW's OCF Yield % is ranked worse than
74.42% of 1419 companies
in the Biotechnology industry
Industry Median: -8.46 vs NRSNW: -27.29

NeuroSense Therapeutics's OCF Margin % for the quarter that ended in Dec. 2025 was %.

NeuroSense Therapeutics OCF Yield % Explanation

Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

NeuroSense Therapeutics OCF Yield % Related Terms

NeuroSense Therapeutics OCF Yield % Historical Data

* Premium members only.

The historical data trend for NeuroSense Therapeutics's OCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NeuroSense Therapeutics OCF Yield % Chart

NeuroSense Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Yield %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

NeuroSense Therapeutics Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
OCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

NRSNW vs SNTI, LSTA, DYAI: OCF Yield % Comparison

For the Biotechnology subindustry, NeuroSense Therapeutics's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NeuroSense Therapeutics OCF Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NeuroSense Therapeutics's OCF Yield % distribution charts can be found below:

* The bar in red indicates where NeuroSense Therapeutics's OCF Yield % falls into.


NRSNW
29GF Score
NeuroSense Therapeutics Ltd NRSNW
OCF Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NeuroSense Therapeutics OCF Yield % Calculation

OCF Yield % is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.

NeuroSense Therapeutics's OCF Yield % for the fiscal year that ended in Dec. 2025 is calculated as

OCF Yield %=Cash Flow from Operations / Market Cap
=-7.671 /
=N/A%

NeuroSense Therapeutics's annualized OCF Yield % for the quarter that ended in Dec. 2025 is calculated as

OCF Yield %=Cash Flow from Operations * Annualized Factor / Market Cap
=-3.671 * 2 /
=N/A%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Yield % →
What does a OCF Yield % of -27.29 mean?
NeuroSense Therapeutics (NRSNW) has a OCF Yield % of -27.29 as of Jun. 25, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on NeuroSense Therapeutics and its competitors. According to the industry distribution chart, NeuroSense Therapeutics ranks #1056 out of 1419 companies in the Biotechnology industry, placing it in the top 74.4%.
Is NeuroSense Therapeutics' OCF Yield % too high?
NeuroSense Therapeutics' current OCF Yield % is -27.29. Based on the distribution chart, NeuroSense Therapeutics ranks #1056 out of 1419 companies in the Biotechnology industry, which is below the industry midpoint. Overall, NeuroSense Therapeutics has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does NeuroSense Therapeutics' OCF Yield % compare to SNTI and LSTA?
According to the Biotechnology industry distribution chart, NeuroSense Therapeutics ranks #1056 out of 1419 companies for OCF Yield %. This places NeuroSense Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on NeuroSense Therapeutics and its competitors. NeuroSense Therapeutics's current OCF Yield % is -27.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeuroSense Therapeutics stock overvalued right now?
NeuroSense Therapeutics (NRSNW) has a current OCF Yield % of -27.29. The current OCF Yield % is -27.29. NeuroSense Therapeutics' overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For NeuroSense Therapeutics (NRSNW), the current OCF Yield % is -27.29 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NeuroSense Therapeutics Business Description

Other Exchanges NRSN:USAH1Z:Germany
Address 11 HaMenofim Street, Building B, Herzliya, ISR, 4672562
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
29GF Score

Get the complete analysis for NRSNW

OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.21
Price